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ABSTRACT: 
Background: It was well studied that HER2/ErbB2/p185 overexpression in human malignant 
cancers  correlates  with  poor  prognosis  and  chemo-resistance.  Meanwhile,  Genistein  (4,5,7-
trihydroxyisoflavone), a major isoflavone component of soybeans and other leguminous plants, 
has been shown to exhibit a potent anti-proliferative effect on some sex hormone dependent 
cancers.  
 
Objective: The effects of genistein on the proliferation of human HER2-overexpressing breast 
and ovarian cancer cell lines were investigated, and the action mechanism was explored. 
 
Methods: Western blotting, fluorescence-activated cell sorting (FACS) and immunofluorescence 
methods, cell proliferation assay kit from Promega and cell apoptosis assay kit from Biolegend 
were used. The dose- or time-response relationship of genistein were observed on the HER2-
negative breast cancer cell line MCF-7 or HER2-positive breast cancer cell lines BT-474 and 
MCF-7/Her2 derived from MCF-7, and ovarian cancer cell line SKOV-3. 
 
Results: The addition of genistein ranged from 1-10g/ml in the medium for 48 hours had a 
marked inhibition on the proliferation of HER2-positive cancer cell lines MCF-7/Her2, BT-474 
and SKOV-3, compared with tamoxifen and DMSO control (P<0.01), and a dose-dependent 
response was presented. However, genistein exerted a weak inhibitive effect on HER2-negative 
breast cancer cell line MCF-7. There was a significant apoptosis or necrosis effect of BT-474 
cells  induced  by  10  g/ml  genistein  for  12-48  hours  in  comparison  with  DMSO  control 
(P<0.01), and a time-dependent response relationship. Moreover, genistein could down-regulate 
HER2 receptor expression and AKT kinase activity by using immunofluorescence and western 
blotting methods. Functional Foods in Health and Disease 2013; 3(7):291-299                                                            Page 292 of 299  
Conclusion: Our findings demonstrated that genistein could effectively inhibit the proliferation 
of HER2-positive cancer cell lines, which should be through down-regulating HER2 receptor 
and downstream signaling. 
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BACKGROUND:  
HER2 (also named ErbB2, p185
her2/neu) is a member of the transmembrane epidermal growth 
factor receptor (EGFR) family. HER2 gene amplification and/or overexpression are found in a 
number of human malignancies including breast, ovarian and gastric cancers, and associated with 
enhanced  cancer  metastasis  and  poor  prognosis.  It  is  shown  that  patients  with  HER2-
overexpressing  cancers  have  lower  long-term  survival  and  disease-free  survival  rates  [1,  2]. 
Although there have been anti-HER2 humanized monoclonal antibody drugs trastuzumab (1998, 
Genentech,  USA)  and  pertuzumab  (2012,  Genentech,  USA)  and  EGFR/HER2  dual  inhibitor 
lapatinib  (2007,  GSK,  Britain)  has  been  proved  for  therapeutic  use  in  patients  with  HER2-
positive metastatic breast cancer patients, many patients either do not respond to the therapy or 
progress for drug resistance [2-5]. In this regard, more HER2-targeted drug researches are being 
needed.  
A number of studies suggest that intake of a soy-rich diet may have a protective effect 
against sex hormone-dependent cancer [6, 7]. Genistein (4,5,7-trihydroxyisoflavone), a major 
isoflavone constituent of soybeans and soy’s products, has been shown to exhibit potent anti-
proliferative effect on various cancer cell lines, both in vitro and in vivo [8–10]. Structurally, 
genistein  resembles  the  biphenolic  17β-estradiol  and  displays  high  binding  affinities  to  the 
estrogen receptors (ER), and hence genistein may mimic and regulate the actions of estrogens by 
acting as either an ER agonist or antagonist [11]. In addition, genistein is also a protein tyrosine 
kinase  inhibitor,  which  may  lead  to  cell  cycle  arrest,  apoptosis,  invasion,  metastasis,  and 
angiogenesi of cancer cells by regulating protein tyrosine kinase mediated signaling pathways [9, 
12]. 
Previously  we  have  found  that  genistein  can  inhibit  the  growth  of  estrogen-dependent 
breast and  endometrial cancer cells in vitro and in vivo (data not shown). In this study, we 
elucidate  a  novel  mechanism  by  which  genistein  mediates  its  effect  on  some  HER2-
overexpression  breast  and  ovarian  cancer  cell  lines  by  down-regulating  HER2  and  in  turn 
downstream  signal  protein  AKT  activity,  which  is  required  for  the  cell  proliferation  and 
metastasis. 
 
MATERIALS AND METHODS:  
Reagents and cell lines: Gensitein (C15H10O5) and tamoxifen (C26H29NO) were obtained 
from  Sigma  Chemical  Co.  Anti-HER2  antibodies  (Ab-1  against  c-terminus  domain,  Ab-20 
against ECD, and Ab-18 against p-HER2 at Tyr1248) were ordered from NeoMarkers. AKT, p-
AKT (Ser473) antibodies were from Cell Signaling. GAPDH antibody was from Santa Cruz. 
HRP-conjugated goat anti-mouse or goat anti-rabbit antibodies were from Pierce. Other reagents 
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Human breast cancer cell lines BT-474, MCF-7 and ovarian carcinoma cell line SKOV-3 
were obtained from the Type Culture Collection of Chinese Academy of Sciences (Shanghai, 
China) in 2012. MCF-7/Her2 was derived from MCF-7 cells through the stable transfection of 
HER2 plasmids in our lab. 
 
Cell  Proliferation  Assay:  BT-474  (2×10
4  cells/well)  and  MCF-7,  MCF-7/Her2  or  SKOV-3 
(5×10
3 cells/well) cells were seeded in 96-well microplates (Costar) and cultured overnight in 
DMEM  with  10%  FBS.  Fresh  medium  containing  the  indicated  concentrations  of  genistein, 
tamoxifen or DMSO were replaced. After incubation for 72 hours, cell proliferation was assessed 
by using CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega). Briefly, 20 
μl MTS solution was added to each well for 1.5 h incubation and the absorbance at 490 nm was 
measured.  
 
Western blot analysis: Equal amounts of proteins (30 μg) from cell lysates were separated by 
10% SDS–PAGE and transferred to nitrocellulose membrane. After blocking with 5% non-fat 
dry milk in PBS containing 0.2% Tween-20, membranes were incubated at 4 °C overnight with 
primary  antibody.  Membranes  were  then  incubated  with  horseradish  peroxidase-conjugated 
secondary antibodies for 2 h. ECL reagent (Pierce) was used for protein detection. 
 
Fluorescent-activated  cell  sorting  and  immunofluorescence:  Fluorescent-activated  cell 
sorting (FACS) was performed using indirect staining protocols. 5 million cancer cells were 
collected and then labeled with primary anti-HER2 antibody (Ab-20, NeoMarkers), then stained 
by secondary antibody with FITC (Sigma).  
For immunofluorescence, cells were  fixed in 4% paraformaldehyde and permeabilized for 
10 min in  PBS containing 0.2% Triton X-100. Cells were washed with PBS  containing 0.02% 
Triton  X-100  and  1.5%  FBS,  followed  by  incubation  with  antibodies  against  HER2  (Ab-1 
against c-terminus domain, Ab-20 against ECD) for 1 hour at room  temperature. Cells were 
incubated  with  FITC  or  Rhodamine-conjugated    secondary  antibody  (Sigma).  Nuclei  were 
visualized by staining with 1 µg/mL DAPI. Images were captured  on a 510 LSM confocal 
microscope (Zeiss). 
 
Statistical  analysis:  Data  is  presented  as  the  mean  ±  SD  from  at  least  three  independent 
experiments. All data analyses were done by software of SPSS13.0 for Windows. P < 0.05 was 
regarded as the threshold value for statistical significance. 
 
RESULTS:  
3.1. Genistein inhibits the proliferation of HER2-overexpression cancer cell lines: Human 
breast cancer cell lines BT-474 and MCF-7/Her2 derived from MCF-7, and ovarian cancer cell 
line SKOV-3 were confirmed to be HER2-overexpressing cells, and the parent cell line MCF-7 
was of low HER2 expression using FACS (Fig. 1A) and western blotting methods (Fig. 1B). 
Among the HER2-overexpressing cancer cells,  SKOV-3 is the most and MCF-7/Her2 is the 
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We then investigated whether genistein treatment had different effects on the proliferation 
of high and low HER2-expressing cancer cell lines. As shown in Fig. 2C , addition of  0.1, 1 and 
10  g/ml  genistein  into  the  medium  significantly  inhibited  the  cell  proliferation  of  MCF-7, 
MCF-7/Her2, BT-474 and SKOV-3 compared with DMSO control (P < 0.01), and showed a 
dose-dependent response relationship. In contrast, 10 g/ml of tamoxifen had only some degree 
of proliferation inhibition on these four cancer cell lines, and the maximum inhibition rate was 
not up to 8%. Moreover, genistein had a more potent inhibition efficay on the three HER2-
overexpressing  cancer  cell  lines  than  MCF-7  with  low  HER2  expression  levels  (P  <  0.01). 
However, tamoxifen did not show so remarkable preference on the HER2-positive MCF-7/Her2 
cells. In addition, we investigated the effect of genistein added in the culture media of human 
normal cell lines such as HEK293 and MCF10A, and the result deminstrated that 10  g/ml 
genistein treatment for 48 hours had no marked influence on the normal cell morphology and 
proliferation (data not shown).  
 
 
 
 
 
 
 
Figure  1.  Genistein  inhibited  the  proliferation  of  HER2-expression  cancer  cell  lines.  A, 
HER2  expression  detection  by  FACS.  B,  HER2  expression  detection  by  western  blotting.  C,  The 
proliferation reduction of cancer cells treated with genistein for 48 hours. CTRL, DMSO control; TAM, 
tamoxifen with 10 g/ml; G1, G2 and G3 mean 0.1, 1 and 10 g/ml genistein, representatively. 
 
3.2. Genistein induces cell apoptosis of HER2-overexpressing cancer cell lines: Consistent 
with the above results, genistein treatment could induce the HER2-overexpression cell apoptosis. 
As shown in Fig. 3, the results showed that 10 g/ml of genistein for 12 hours was able to induce 
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response relationship. In contrast, 10 g/ml of tamoxifen treatment BT-474 cells for 48 hours, 
cell  death  (apoptosis  and  necrosis  ratio)  is  much  smaller  than  that  of genistein  in  the  same 
processing conditions (P < 0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Genistein induced the apoptosis of BT-474 cells. A, FACS detection result using double 
staining of annexin V and prodium iodide (PI). B, statistical result of A figure. CTRL, DMSO control; 
TAM, 10 g/ml tamoxifen for 48 hours; G-12h, G-24h and G-48h mean 12, 24 and 48 hours treated with 
10 g/ml genistein, representatively. 
 
3.3.  Genistein  decreases  HER2  receptor  and  downstream  signaling  of  cancer  cells:  To 
investigate the underlying mechanism by which genistein targets HER2 receptor property, we 
tested  whether  genistein  can  affect  the  expression  of  HER2  receptor  and  HER2  signal 
transduction. Interestingly, genistein treatment resulted in significant downregulation of HER2 
receptor and suppression of the downstream AKT activity of BT-474 or other HER2-positive 
cancer cells (Fig. 3A). 
To further confirm the downregulation of HER2 receptor by genistein, we observed HER2 
protein level in SKOV-3 cells treated with genistein using laser confocal microscope. It was 
shown  that  genistein  was  able  to  decrease  HER2  receptor  expression  of  SKOV-3  cells  and 
induce the endocytosis of HER2 receptor (Fig. 3B).  Functional Foods in Health and Disease 2013; 3(7):291-299                                                            Page 296 of 299  
 
 
Figure  3.  The  decreased  HER2  receptor  and  downstream  signaling  of  cancer  cells  by 
genistein. A, The changes of HER2 receptor and downstream signaling of BT-474 cells treated with the 
indicated concentration of genistein for 4 hours or 1 g/ml genistein for the shown time by western 
blotting. B, The changes of HER2 receptor of SKOV-3 cells treated with 2 g/ml genistein for 4 hours by 
immunofluorescence. Immunofluorescence was performed using anti-HER2 antibodies (Ab-1 against c-
terminus  domain,  Ab-20  against  ECD).  Cells  were  counterstained  with  DAPI  to  show  the  nuclear 
morphology. CTRL, DMSO control; TAM, tamoxifen with 2 g/ml for 4 hours; GEN, genistein. 
 
DISCUSSION:  
Many human cancers express HER2, which acts as the preferred heterodimerization partner for 
other  members  of  ErbB  receptors  (named  ErbB1/EGFR,  ErbB3  and  ErbB4)  and  stimulates 
several downstream signaling cascades such as MAPK and PI3K/AKT pathways [1]. Because of 
these properties, HER2 has currently become one of the most important cancer markers, which 
contribute to resistance to therapy, cancer recurrence and metastasis. Thus, targeting HER2 is 
crucial for curative therapies in HER2-positive cancer patients [2]. Here, we demonstrated for 
the first time that genistein has potent inhibition effects on HER2-positive breast and ovarian 
cancers in vitro. Furthermore, we showed that these effects were due to the downregulation of 
HER2 receptor and downstream signaling by genistein. 
One  of  the  key  properties  of  cancer  cells  is  their  proliferation  ability,  and  currently, 
genistein has been reported to have remarkable proliferation inhibition capability on prostate, 
bladder and other cancers [8-13]. Our previous result has demonstrated that genistein can inhibit Functional Foods in Health and Disease 2013; 3(7):291-299                                                            Page 297 of 299  
the growth of estrogen-dependent breast and endometrial cancer cells in vitro and in vivo, which 
is considered to be mainly through antagonizing with estrogen. In this study, we further found 
that genistein had a more significant proliferation inhibition and apoptosis induction capacity on 
HER2-positive breast cancer cell line MCF-7/Her2 than HER2-negative parent cell line MCF-7 
in  a  time-  or  dose-dependent  manner.  In  the  other  regard,  the  effect  of  genistein  was  more 
remarkable on all the cancer cell lines in our study, i.e. BT-474, SKOV-3, MCF-7/Her2 and 
MCF-7, than tamoxifen which is an antagonist of the estrogen receptor and has been widely used 
in clinic [14]. The findings implied that genistein was not only an antagonist of the estrogen 
receptor, and there was a new mechanism of genistein anti-cancer function. By analyzing the 
mechanism, it was confirmed that genistein could downregulate HER2 receptor and induce its 
endocytosis, and also suppress its downstream AKT activity, which is a serine/threonine-specific 
protein  kinase  and  plays  a  key  role  in  cell  proliferation,  apoptosis,  transcription  and  cell 
migration [15].  
A number of reports in 2006 and 2007 described that geldanamycin and its analogues had 
potent antiproliferative activity in many cancer cell lines and also decreased cellular levels of 
client proteins involved in cancer cell survival, including mutated p53, Akt and HER2, through 
binding to heat shock protein (Hsp)90 and inhibiting its ATPase activity [16,17]. So it is clear 
that the anti-cancer effects and pathways of geldanamycin and its analogues are similar with 
those of genistein. However, Basak Shashwati reported that genistein might induce an epigenetic 
change  by  its  antiestrogenic  activity  to  inhibit  Hsp90  activity,  which  was  distinct  from 
geldanamycin and its analogues [18]. For this regard, the details need be further explored. 
 
CONCLUSION:  
In conclusion, our findings demonstrate for the first time that genistein, a natural compound,  
may be effective for HER2-positive cancer prevention and treatment, and its action may be, at 
least in part, via targeting HER2 receptor and its signaling pathway. 
  
Abbreviations: ECD, extracellular domain; EGFR, epidermal growth factor receptor; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; Hsp90, heat shock protein 90; MAPK, mitogen-
activated protein kinase; p-AKT, phosphorylated AKT. 
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